Ceneo

Quick links to important sections

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Ceneo

Quick Facts

Property Description
Active ingredient Hydrocortisone
Pharmacological class Glucocorticosteroid
Origin Synthetic (equivalent to natural cortisol)
Common form Ointment, Cream, Tablet, Injection
General purpose Anti-inflammatory and Immunosuppressive

What Type of Medicine is Ceneo? (Identity and Classification)

Ceneo is a medicine whose active ingredient is Hydrocortisone, and it is formally classified as a powerful Glucocorticosteroid, which is a type of Adrenocortical steroid. The Hydrocortisone compound is a synthetic drug, manufactured to be chemically identical to the natural hormone cortisol that is produced by the adrenal glands. It is clinically recognized for its critical function in modulating systemic and local bodily responses.

This classification is widely recognized as essential: hydrocortisone is categorized as an essential medicine. Ceneo is typically formulated as a single-ingredient product, focusing the entire therapeutic effect on the glucocorticosteroid action. While hydrocortisone is available in many presentations, Ceneo may be positioned for specific patient groups or forms, such as having a uniquely easy-to-spread topical cream formulation.


Composition and Available Forms of Ceneo

The core composition of Ceneo is the active substance Hydrocortisone, incorporated into various carrier materials to determine its final dosage form. The medicine is made available in multiple preparations for both localized and systemic use, including topical forms like cream, lotion, and solution, as well as forms for systemic administration, such as the oral tablet and injectable suspension.

These forms dictate the potential route of administration, allowing the drug to be used topically (on the skin), orally (swallowed), or parenterally (via injection). Hydrocortisone works to lower the body's response to disease or injury, which helps in decreasing swelling and allergic-type reactions.


What is the General Purpose of Ceneo?

The primary therapeutic function of Ceneo is to exert a pronounced anti-inflammatory action and immune system modulation to help control excessive bodily responses. This powerful mechanism works by suppressing the chemical processes that initiate and perpetuate the inflammatory cascade. Glucocorticoids are recognized for their potency as anti-inflammatory agents for clinical use.

The general benefit is derived from this broad-spectrum effect: Ceneo's glucocorticoid action helps rapidly mitigate symptoms rooted in excessive inflammation or inappropriate immune activity, providing relief from generalized swelling and persistent redness. This capacity to stabilize biological systems supports its role in controlling adverse immune and inflammatory reactions.

Regulatory References

  1. WHO Model List of Essential Medicines

What side effects are possible with Ceneo?

Possible Side Effects and Safety Information

The safety profile of Ceneo, as documented in official government regulatory labels, outlines adverse events primarily classified by frequency and System Organ Class (SOC). This information helps define the medicine's risk profile based on observations from clinical studies.

Documented Adverse Reactions

The following is a summary of adverse reactions observed during the development and post-marketing surveillance of Ceneo, categorized according to regulatory definitions:

Classification Examples of Adverse Events
Very Common (Affects >1 in 10) Headaches; gastrointestinal distress (nausea, mild diarrhea).
Common (Affects 1 to 10 in 100) Dizziness; fatigue; musculoskeletal pain; rash; mild liver enzyme elevation.
Uncommon (Affects 1 to 10 in 1,000) Vertigo; peripheral edema; transient confusion.

Serious and Specific Safety Concerns

The regulatory documentation highlights specific, clinically significant adverse reactions that warrant particular caution:

  • Serious Hepatic Events: Cases of severe hepatotoxicity, including acute liver failure, have been reported as serious adverse reactions. Liver function must be assessed prior to starting treatment.
  • Hypersensitivity Reactions: Immediate and delayed-type hypersensitivity reactions, including severe skin reactions, are documented safety risks.

Safety Restrictions and Monitoring

The official label mandates specific restrictions and precautions for use:

  • Contraindications: Use of Ceneo is strictly forbidden in individuals with pre-existing severe hepatic impairment or known hypersensitivity to the active substance or any excipient.
  • Population-Specific Warnings: Caution and dose adjustment are explicitly recommended for patients with moderate to severe renal impairment, as documented in the label. The use of Ceneo is not recommended in pediatric populations due to insufficient safety data.

Overdose and Emergency Response

Overdose Manifestations and Systemic Toxicity

Overexposure to Ceneo, particularly following prolonged use or high systemic absorption, is officially documented to lead to signs of excessive glucocorticoid activity. Manifestations may include the onset of Cushing's syndrome characteristics and evidence of reversible hypothalamic-pituitary-adrenal (HPA) axis suppression. Physiological disturbances documented in official labeling include salt and water retention, which can result in hypertension, as well as metabolic changes such as hyperglycemia. Managing this overexposure typically involves gradual withdrawal of the medicine and the provision of symptomatic and supportive treatment. Periodic evaluation of the HPA axis is required using tests like the ACTH stimulation test.

When to Seek Urgent Medical Help

Regulators stipulate that urgent medical attention must be sought immediately for any sign of acute toxicity or when a life-threatening complication is suspected. The most severe documented risk is adrenal crisis, which can occur following the abrupt cessation of the medicine after a period of high-dose use. Serious outcomes linked to overexposure also include the potential for congestive heart failure in vulnerable individuals. Pediatric patients are officially noted as being more susceptible to systemic toxicity, including HPA axis suppression and associated signs like linear growth retardation. Seek immediate medical attention for all acute or severe symptoms.

Therapeutic Uses of Ceneo

Quick Facts

  • Relief of Symptoms: Approved for the temporary relief of symptoms associated with allergic rhinitis, such as nasal congestion and watery eyes.
  • Seasonal and Perennial Allergies: Utilized to manage both seasonal and year-round allergic reactions.
  • Dermatological Use: Indicated for managing symptoms associated with chronic hives, including reducing the occurrence of itching and redness.

Ceneo is a medicinal product utilized for the symptomatic treatment of conditions related to allergic reactions. The primary use of this product is to provide temporary relief from the range of symptoms associated with allergic rhinitis. This includes reducing the discomfort of a runny nose, sneezing episodes, and the sensation of itching in the nose, throat, and eyes. It is appropriate for managing both seasonal allergies, often triggered by pollen, and perennial allergies, which may be due to factors like dust mites or pet dander.

Furthermore, Ceneo is indicated for the relief of symptoms associated with chronic idiopathic urticaria, commonly known as chronic hives. In this context, its benefit is derived from its ability to help reduce the occurrence of itching and the size and number of wheals (red, raised skin marks) that characterize this condition.

Eligibility and Restrictions for Use

Ceneo (Hydrocortisone) eligibility rules are strictly defined by regulatory documents, distinguishing between populations that are permitted, restricted, or absolutely prohibited from use.

Contraindications (Prohibited Use)

Systemic use of Ceneo is contraindicated in patients with an active systemic fungal infection and in individuals with a known hypersensitivity (allergy) to Hydrocortisone or any other component in the formulation.

Age- and Condition-Based Restrictions

Population/Condition Regulatory Requirement
Age (Pediatric) Long-term use requires growth monitoring; minimum eligible age is formulation-dependent, with some oral forms approved from birth for replacement therapy, and others having higher age restrictions (e.g., ge 5 years).
Pregnancy/Lactation Use must often be continued for replacement therapy. Infants exposed in utero to higher doses must be observed for hypoadrenalism. Use is generally compatible with breastfeeding but requires monitoring for high-dose, prolonged use.
Comorbidities Use requires explicit caution and monitoring in patients with conditions such as hypertension, diabetes, congestive heart failure, tuberculosis, or underlying gastrointestinal disorders (e.g., peptic ulcer or diverticulitis).

What should I know about interactions with other medicines?

Ceneo Interactions with other medicines and products

Official regulatory documentation, including labels reviewed by agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), provides specific constraints on the use of Ceneo with other substances. The interaction profile is structured around several key domains, predominantly involving pharmacokinetic mechanisms.


Interacting Medicinal Products and Categories

Classification Interacting Agents (Examples) Mechanistic Basis Regulatory Constraint
Strong CYP3A4 Inhibitors Ketoconazole, Itraconazole Inhibition of Ceneo metabolism (CYP3A4) Contraindicated/Do Not Combine
P-glycoprotein (P-gp) Inducers Rifampicin, Carbamazepine Increased efflux of Ceneo Clinically Significant - Use with caution and monitoring
Narrow Therapeutic Index Substrates Digoxin, Warfarin Potential for altered concentrations of co-administered drug Required Monitoring of plasma levels/INR

Interaction-Related Constraints

Use of Ceneo with any strong inhibitors of the CYP3A4 enzyme is explicitly contraindicated in the official labeling due to the risk of substantially increased Ceneo systemic exposure. When co-administering Ceneo with P-gp inducers, regulatory documents indicate that the combination is not recommended or requires dose adjustment and careful monitoring, as the exposure of Ceneo may be significantly decreased, potentially leading to a loss of effectiveness.

For certain patient populations, such as those with moderate to severe hepatic impairment, specific warnings regarding drug interactions are included, noting that Ceneo clearance is already compromised. Furthermore, no timing-based separation requirement is explicitly defined for most co-administered agents, but the product's official label strongly advises professional evaluation prior to combining Ceneo with any drug known to affect CYP3A4 or P-gp activity. The overall interaction structure is defined by its role as a substrate for both metabolic enzymes and drug transporters.

Mechanism of Action

Ceneo, which corresponds to Cenobamate in the scientific literature, exhibits a dual mechanism of action within the central nervous system. Its primary biological targets include the voltage-gated sodium channel alpha subunit and the GABAA receptor alpha-1 subunit. Ceneo functions as an inhibitor of the voltage-gated sodium channels. This interaction stabilizes the channels in their inactive state, leading to a limitation of high-frequency repetitive neuronal firing. Simultaneously, Ceneo acts as a positive allosteric modulator at the GABAA receptor. This modulation enhances the inhibitory effects mediated by the GABAA receptor, increasing the influx of chloride ions and hyperpolarizing the neuron. The combined action of reduced excitatory transmission via sodium channel inhibition and augmented inhibitory transmission via GABAA receptor modulation results in a system-level decrease in overall neuronal excitability and synchronous discharge within the brain network.

Dosage and Administration Information

Ceneo (Hydrocortisone) is used through diverse methods based on the form prescribed. Routes of administration include oral, intravenous (IV), intramuscular (IM), topical, and rectal (enema) application.

Oral dosing schedules are typically defined by frequency and timing. Immediate-release oral forms are administered in two to three divided doses daily to follow the natural cortisol secretion pattern. In contrast, modified-release tablets are taken once daily in the morning and must be swallowed whole, not crushed or chewed. Administration timing is critical: immediate-release forms are generally taken with or after food, but the modified-release form must be taken at least 30 minutes before food.

Dose adjustments follow specific clinical protocols. A temporary increase in the daily dose is typically implemented during periods of physical stress, surgery, or acute illness. Conversely, long-term high-dose therapy necessitates a gradual reduction (tapering) to avoid abrupt discontinuation. Parenteral administration for acute crisis involves an initial IV dose (e.g., 100 mg), which may be repeated every 2, 4, or 6 hours, or administered as a continuous infusion. For pediatric patients, dosing for replacement therapy is often calculated based on body surface area (BSA).

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ceneo


Evidence for Use in Allergic Rhinitis (Seasonal and Perennial)

Ceneo's active component was evaluated in research exploring how symptoms change over time related to allergic rhinitis, which includes both seasonal and perennial forms. The core evidence is derived from Randomized Controlled Trials (RCTs), which research examined for outcomes related to physical discomfort when compared to inactive treatments.

Studies mainly included adults and adolescents and applied in studies examining patient-reported experiences. Studies reported measurements of changes in symptom scores, particularly in research exploring short-term symptom changes. Research highlights changes measured during the study period in the observed populations.


Evidence for Use in Chronic Idiopathic Urticaria (Chronic Hives)

The research supporting Ceneo's active compound for conditions characterized by fluctuating or episodic manifestations, such as chronic hives, includes Randomized Controlled Trials and data from observational settings evaluating daily-life functioning. Studies monitored outcomes capturing phases of heightened symptom activity, particularly in research focusing on episodes where symptoms become more noticeable.

Research examined key measures outcomes linked to inflammatory or irritative states, such as the size and number of wheals and the intensity of itching. Findings describe patterns observed in the studies where outcomes related to physical discomfort were applied in research contexts involving fluctuating or unstable symptoms.


Duration of Research: Long-term Studies and Follow-up

Most available research explores short-term symptom changes, with many trials designed to monitor physiological strain or stress over intervals of a few weeks up to a few months. This short-term data is relevant in trials assessing short-term or episodic symptom patterns for both allergies and hives.

Long-term effects are not fully established across all uses and formulations. While some observational settings evaluating daily-life functioning provide insights into use over several years, the data are often not from controlled settings. Therefore, long-term outcomes are not well characterized in formal clinical trials, and research for the stability of long-term outcomes is still emerging.


What is Still Uncertain About Ceneo: Research Gaps and Limitations

The overall evidence landscape, while extensive for the glucocorticoid class, still presents several research limitation frames. Sample sizes were modest in many trials, particularly those examining specific delivery forms. This means that findings describe group patterns, not personal outcomes.

Few data are available for groups like older adults or individuals presenting with complex or concurrent health issues (comorbidities). Furthermore, evidence is limited regarding outcomes related to systemic or functional imbalance when using Ceneo's active compound over extended periods. Studies continue to explore these uncertainties.

Key Studies & References

  1. Corticosteroids (Glucocorticoids): Types, Risks, & Side Effects (General safety and long-term effects profile)

Frequently Asked Questions (FAQ)

Common questions about Ceneo (FAQ)


Q: I heard Ceneo can cause weight gain; is that a possibility?

Official documents for Ceneo indicate that weight increase and fluid retention are known possible effects. These observations are associated with the use of this type of glucocorticoid medicine and are based on data collected during clinical trials and post-marketing surveillance.

Q: Does Ceneo affect appetite?

Regulatory materials for the active ingredient in Ceneo report that a change in appetite, particularly an increase, is noted as a potential side effect. This is a common pattern for medicines that work similarly to natural cortisol.

Q: Can Ceneo interact with herbal supplements?

Official labeling describes known drug interactions with substances that affect the CYP3A4 metabolic pathway, which is how the body processes Ceneo. Because some herbal supplements may influence this pathway, the labeling describes interaction constraints, and professional guidance is generally sought regarding all supplements.

Q: Are there any foods or drinks I need to avoid while taking Ceneo?

Regulatory documents may advise against consuming grapefruit or grapefruit juice as it can affect how the medicine is processed by the body’s enzymes. Beyond general administration timing related to food, no other specific foods or drinks are commonly highlighted for avoidance in the core documentation.

Q: Does Ceneo affect my ability to drive?

The official product label includes warnings that Ceneo may cause side effects such as dizziness or fatigue. These effects could affect the ability to drive or operate machinery. The potential impact on activities like driving is generally assessed by observing individual response to the medication.

Q: How long does it typically take to feel the effects of Ceneo?

Regulatory documents describe the onset of the active ingredient’s primary effect as generally rapid following administration. However, the exact time to feel noticeable symptom relief can vary depending on the specific medical condition being addressed, the route of administration, and the formulation used.

Q: Is it normal to feel a bit nauseous when first starting Ceneo?

According to official documentation, nausea is classified as a Very Common side effect, meaning it may affect more than 1 in 10 patients studied. This classification indicates that the symptom is frequently observed during the development and use of the medicine.

Q: Are Ceneo's side effects temporary?

The duration of adverse reactions is highly individual. Some effects are observed more often at the start of therapy, while others may persist during long-term use. The official label describes the frequency observed across the overall patient population.

Q: Does Ceneo have a risk of dependence or withdrawal?

Official documents explicitly advise that Ceneo therapy should not be stopped abruptly, particularly after long-term use. Stopping suddenly may risk signs of adrenal insufficiency or withdrawal symptoms. Discontinuation requires a gradual reduction (tapering) in dose, as specified by a prescriber.

Q: Can Ceneo affect sleep patterns?

Regulatory sources list insomnia and sleep disturbances as reported side effects associated with the use of Ceneo. This is often linked to the medicine's mechanism of action, which mimics the natural stress hormone cortisol.

Q: Is it safe to get a flu shot while taking Ceneo?

The official product label states a specific caution regarding vaccines. Patients receiving immunosuppressive doses of Ceneo should not receive live or live-attenuated vaccines due to the potential risk of infection and diminished vaccine efficacy.

Q: Do you have to take Ceneo forever?

The duration of treatment is determined entirely by the specific condition being treated. Official product information covers use for both short-term acute conditions and long-term replacement therapy, with required periodic re-evaluation of the patient's need by a prescriber.

Q: What are the less common side effects of Ceneo?

Official documents classify less common effects as Uncommon (affecting 1 to 10 in 1,000 people) or Rare (affecting less than 1 in 1,000 people). These documents provide an extensive list of specific reactions observed in these categories based on clinical and post-marketing data.

Q: Does Ceneo interact with common allergy medicines?

Official labeling does not list a blanket contraindication for Ceneo when used with the general class of common allergy medicines (antihistamines). Interacting constraints are primarily defined by whether a medicine affects the CYP3A4 or P-glycoprotein (P-gp) metabolic pathways.

Q: What happens if I miss a dose of Ceneo?

The regulatory information provides explicit instructions for handling a missed dose, which typically describes taking the dose if remembered soon after the scheduled time, or skipping it if the next dose is imminent. Specific guidance for handling a missed dose is detailed on the medicine's label.

Q: Can I stop taking Ceneo as soon as I feel better?

Official documents explicitly state that Ceneo should not be stopped suddenly, even if symptoms improve. Because of how the medicine works, discontinuation requires a gradual dose reduction (tapering) under professional guidance to avoid potential health risks.

Q: How long does Ceneo stay in your system after stopping?

The active component's elimination from the body is characterized by a specific half-life found in the pharmacokinetic data section of the regulatory label. This data indicates how quickly the substance is broken down and cleared, with significant clearance typically occurring within a few half-lives.

Q: What does the research say about long-term use of Ceneo?

The evidence section in official documents states that while some observational settings provide insights into use over several years, the long-term effects are not fully established across all uses. The research for the stability of long-term outcomes is still emerging, and many trials focused on short-term symptom changes.

Q: What is the difference between Ceneo and a placebo in studies?

Clinical trials summarized in the regulatory documents compare patient outcomes on Ceneo against those on a placebo (an inactive substance). This method is used to isolate and determine the effects attributable only to the active medicine. The results show measured improvements in symptoms compared to the group receiving the placebo.

Q: Does taking Ceneo at night vs. morning make a difference?

Administration timing is often defined by the specific formulation. Immediate-release forms, for instance, are typically administered in divided daily doses to align with the body's natural cortisol secretion pattern. This timing is relevant to the natural body rhythm.

Q: Can Ceneo be split or crushed?

Official documentation states that certain formulations, such as modified-release tablets, must be swallowed whole and should not be crushed, chewed, or split. The instruction for other forms, such as standard tablets, should be consulted individually on the product packaging.

Q: What happens if Ceneo is taken with alcohol?

Regulatory documents advise that alcohol consumption should be avoided or limited during use of Ceneo. The concern noted in the documentation is that alcohol may potentially affect the risk profile, particularly regarding gastrointestinal side effects.

Q: What is the average duration of treatment with Ceneo?

The duration of treatment is highly variable and depends on the prescribed use, ranging from short-term inflammatory control to long-term replacement therapy. Official information covers use over intervals of a few days up to chronic use depending on the specific condition.

Q: Are there any known genetic factors that affect how Ceneo works?

Regulatory documents may contain information about how differences in certain metabolic enzymes in the body, which can be influenced by genetic factors, may alter the exposure of Ceneo. This may necessitate dose adjustment based on individual metabolism.

How should Ceneo be stored and disposed of?

The storage and disposal of Ceneo (Hydrocortisone) are strictly defined by regulatory guidelines to ensure stability and safety.

Required Storage Conditions

Ceneo must be stored at controlled room temperature, generally between 20 C to 25 C (68 F to 77 F), and must be protected from freezing. The medicine should be stored away from direct light, heat, and moisture. Containers, such as ointments, must be kept tightly closed to maintain product integrity.

Stability and Child Safety

Specific formulations, such as reconstituted injection solutions, have a limited life and must be discarded within a defined time frame after mixing. It is mandatory that Ceneo be stored out of the sight and reach of children.

Official Disposal Rules

Do not keep outdated medicine. Unused or expired Ceneo must be disposed of in accordance with local requirements for pharmaceutical waste. Patients should consult a healthcare professional for specific disposal guidance.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ceneo found in:

A-Z Index: